Diagnostics Service

PLL THERAPEUTICS

PLL Therapeutics’ approach: an overview

Our approach aims at addressing the key unmet needs in the treatment of ALS:

  • Early prediction diagnostics: start treatment as soon as possible
  • Treatment follow-up: monitor patients using blood biomarker companion diagnostics test and assess disease progression
Disease evolution

  • 1 | EARLY DIAGNOSIS

    • Early-stage diagnostics using seric antibodies to identify the level of gut dysbiosis occurring in the bloodstream
    • Early predictive diagnostics to validate ALS or other neurodegenerative diseases in pre-symptomatic patients
    • Diagnostics to monitor the evolution of the disease

  • 2 | TREATMENT FOLLOW-UP

    • Adaptation of treatment regimen (dose, timing, frequency, duration; etc.) thanks to companion diagnostics
    • Better response and increased life expectancy
    • Patient follow-up every 3 to 6 months

The PLL Therapeutics approach: diagnostics

Development of an accurate diagnostics solution to detect and monitor the disease

  • Dedicated diagnostics kit (ALS)

    Confirmation of ALS diagnosis + patient follow-up

    SPECIFICS MARKERS LINKED TO ALS DISEASE METABOLISM AND GUT DYSBIOSIS